Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem rak przełyku (typ płaskonabłonkowy)
- •Przebyta operacja usunięcia przełyku z usunięciem węzłów chłonnych bez chemioterapii lub radioterapii
- •Dostępne próbki tkanki do badania
- •Co najmniej 2 lata obserwacji po operacji z pełną dokumentacją
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Brak informacji klinicznych w ciągu 2 lat po operacji
- •Nowotwory wieloogniskowe lub inne równoczesne nowotwory
Simplified criteria — AI translation
Trial details
- Minimum age
- 20 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Nagoya University
Nagoya, Japan
Yamanashi Universiy
Chūō, Japan
Trial contact
Ajay Goel, PhD
Koichi Takiguchi, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.